Naidoo A, Chirehwa M, McIlleron H, Naidoo K, Essack S, Yende-Zuma N, Kimba-Phongi E, Adamson J, Govender K, Padayatchi N, Denti P.
Journal of Antimicrobial Chemotherapy 2017 February. doi: 10.1093/jac/dkx004.
Singh JA, Abdool Karim SS.
The Lancet Global Health 2017; 5(4): e387-e389.
Gregson J, Kaleebu P, Marconi VC, van Vuuren C, Ndembi N, Hamers RL, Kanki P, Hoffmann CJ , Lockman S, Pillay D, de Oliveira T, Clumeck N, Hunt G, Kerschberger B, Shafer RW, Yang C, Raizes E, Kantor R, Gupta RK.
Lancet Infectious Diseases 2017; 17(3):296-304.
Haffejee F, Naicker T, Singh M, Kharsany AB, Adhikari M, Singh R, Maharaj N, Moodley J.
Journal of Obstetrics and Gynaecology 2017; 37(1):48-52.
Moore PL, Gorman J, Doria-Rose NA, Morris L.
Immunological Reviews 2017; 275(1):217-229.
Ramsuran V, Hernandez-Sanchez PG, O'HUigin C, Sharma G, Spence N, Augusto DG, Gao X, Garcia-Sepulveda CA, Kaur G, Mehra NK, Carrington M.
Journal of Immunology 2017; 198(6):2320-2329.
CAPRISA was created in 2001 and formally established in 2002 under the NIH-funded Comprehensive International Program of Research on AIDS (CIPRA) by five partner institutions; University of KwaZulu-Natal, University of Cape Town, University of Western Cape, National Institute for Communicable Diseases, and Columbia University in New York. CAPRISA is a designated UNAIDS Collaborating Centre for HIV Prevention Research. The main goal of CAPRISA is to undertake globally relevant and locally responsive research that contributes to understanding HIV pathogenesis, prevention and epidemiology as well as the links between tuberculosis and AIDS care.